The New Antipsychotics and Their Therapeutic Potential
- 1 May 1997
- journal article
- Published by SLACK, Inc. in Psychiatric Annals
- Vol. 27 (5) , 320-331
- https://doi.org/10.3928/0048-5713-19970501-04
Abstract
No abstract availableThis publication has 50 references indexed in Scilit:
- P-4-69 Olanzapine in the treatment of dopaminomimetic psychosisEuropean Neuropsychopharmacology, 1995
- P-4-62 Seroquel™ and chlorpromazine in the treatment of hospitalised patients with acute exacerbation of subchronic and chronic schizophrenia. A multicentre, double-blind controlled studyEuropean Neuropsychopharmacology, 1995
- ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophreniaClinical Therapeutics, 1995
- ICI 204,636 (SEROQUEL™): A Dibenzothiazepine Atypical Antipsychotic. Review of Preclinical Pharmacology and Highlights of Phase II Clinical TrialsCNS Drug Reviews, 1995
- The acute effect of sertindole on brain 5-HT2, D2 and ?1 receptors (ex vivo radioreceptor binding studies)Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1992
- ClozapineDrugs, 1990
- Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patientsPsychopharmacology, 1989
- Side effects of clozapinePsychopharmacology, 1989
- In vivo potencies of antipsychotic drugs in blocking alpha 1 noradrenergic and dopamine D2 receptors: Implications for drug mechanisms of actionLife Sciences, 1986
- Antipsychotic drug doses and neuroleptic/dopamine receptorsNature, 1976